Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia

被引：3
|
作者：
Haddad, Fadi [1 ]
Kantarjian, Hagop [1 ]
Issa, Ghayas C. [1 ]
Jabbour, Elias [1 ]
Sasaki, Koji [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Unit 428, Houston, TX 77030 USA
来源：
LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 07期
关键词：
PERIPHERAL NEUROPATHY; IMATINIB; DASATINIB; THERAPY; EDEMA;
D O I：
10.1080/10428194.2022.2045599
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1714 / 1717
页数：4
相关论文
共 50 条
  • [31] The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients with Chronic Myeloid Leukemia
    Ercaliskan, Abdulkadir
    Eskazan, A. Emre
    [J]. CANCER, 2018, 124 (19) : 3806 - 3818
  • [32] Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia
    Vinhas, Raquel
    Fernandes, Alexandra R.
    Baptista, Pedro V.
    [J]. MOLECULAR THERAPY-NUCLEIC ACIDS, 2017, 7 : 408 - 416
  • [33] Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib
    Singh Anand, Anand Prakash
    Umbarkar Prachi, Prachi
    Tousif, Sultan
    Lal, Hind
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 316 : 214 - 221
  • [34] Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
    Soverini, Simona
    Branford, Susan
    Nicolini, Franck E.
    Talpaz, Moshe
    Deininger, Michael W. N.
    Martinelli, Giovanni
    Mueller, Martin C.
    Radich, Jerald P.
    Shah, Neil P.
    [J]. LEUKEMIA RESEARCH, 2014, 38 (01) : 10 - 20
  • [35] STUDY OF MUTATIONS IN THE KINASE DOMAIN OF BCR-ABL1 BY NGS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
    Stuckey, Ruth
    Florido, Ortega Yanira
    Rodriguez, Lopez Juan Francisco
    Bilbao, Sieyro Cristina
    Gomez, Casares Maria Teresa
    [J]. HAEMATOLOGICA, 2020, 105 : 239 - 239
  • [36] A Common but Overlooked Mechanism of BCR-ABL1 Kinase Inhibitor Resistance in Chronic Myeloid Leukemia
    Bruey, Jean-Marie
    Kantarjian, Hagop M.
    Ma, Wanlong
    Yeh, Chen-Hsiung
    Lee, Tai-Sung
    O'Brien, Susan
    Giles, Francis
    Estrov, Zeev
    Cortes-Franco, Jorge
    Albitar, Maher
    [J]. BLOOD, 2009, 114 (22) : 857 - 858
  • [37] BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia
    Schiffer, Charles A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (03): : 258 - 265
  • [38] Assessment of BCR-ABL1 transcript levels at 3 months is the major determinant for outcome in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
    Katalinic, D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 72 : S100 - S100
  • [39] Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia
    Krumbholz, Manuela
    Karl, Matthias
    Tauer, Josephine T.
    Thiede, Christian
    Rascher, Wolfgang
    Suttorp, Meinolf
    Metzler, Markus
    [J]. GENES CHROMOSOMES & CANCER, 2012, 51 (11): : 1045 - 1053
  • [40] Combination of BCR-ABL1 Tyrosine Kinase Inhibitors with a Small Molecule LIM kinase1/2 Inhibitor in BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
    Braun, Thorsten
    Berrou, Jeannig
    Prudent, Renaud
    Djamai, Hanane
    Dupont, Melanie
    Kaci, Anna
    Adiceam, Emilie
    Paublant, Fabrice
    Baruchel, Andre
    Ghysdael, Jacques
    Gardin, Claude
    Dombret, Herve
    [J]. BLOOD, 2018, 132
12345